NISIT RAWO
Alzheimer’s drug developer Cassava Sciences (NASDAQ:SAVA) has struck a consulting agreement with its former chief executive officer, Remi Barbier, nearly two months after his resignation.
The non-exclusive agreement will initially run for a period of one year, during which Barbier is